SLN 10-KMar 5 '26
“Collaboration Agreement with AstraZeneca In March 2020, we entered into a collaboration agreement with AstraZeneca to discover, develop and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases.”
ADCT 10-KMar 10 '26
“Our current ZYNLONTA pipeline utilizes our highly potent pyrrolobenzodiazepine ("PBD") dimer technology (under license from AstraZeneca).”